------------ ------------ ------------ ------------
------------ ------------ ------------ ------------
Supplemental
Information
Cash interest
received 224,636 308,755 325,244 912,394
Cash interest paid 25,123 47,864 53,878 99,206
Non-cash transactions
Capital items
included in
accounts payable 24,831 824,063 24,831 824,063
------------ ------------ ------------ ------------
------------ ------------ ------------ ------------
'/>"/>SOURCE SemBioSys Genetics Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 Related biology technology :1.
SemBioSys submits IND for safflower-produced insulin to U.S. FDA2.
SemBioSys Demonstrates Functionality of its Safflower Produced Apo AI(Milano)3.
SemBioSys to present at the Needham & Company Biotechnology and Medical Technology Conference4.
SemBioSys provides update on shrimp feed additive, Immunosphere(TM)5.
SemBioSys announces first quarter 2008 financial and operational results6.
SemBioSys receives milestone payments from AVAC Ltd.7.
SemBioSys initiates toxicology study for safflower-produced insulin8.
SemBioSys announces 2007 financial and operational results9.
SemBioSys GLA Partner Enters Strategic Alliance for the Sales and Marketing of GLA-Rich Safflower Oil10.
SemBioSys awarded key patent for the production of oleosome emulsions by the European Patent Office11.
SemBioSys to present at the 10th Annual BIO CEO & Investor Conference